Announcement
Sativa Group PLC : Significant Contract with Alliance Healthcare
RNS Number : 5499B
Sativa Group PLC
31 January 2020
|
Press Release
|
31st January 2020
|
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.
Sativa Group Plc
("Sativa" or "the Company" or "the Group")
Goodbody Botanicals signs deal with Alliance Healthcare
for product distribution to UK Pharmacies
Sativa Group Plc subsidiary Goodbody Botanicals has secured a product listing agreement with Alliance Healthcare ("Alliance"), one of the leading distributors and wholesalers of pharmaceutical, medical and healthcare products in the UK and Europe. This gives Alliance's 10,000+ high street retailer customers access to the Goodbody Botanicals range of market-leading CBD products. Alliance Healthcare services independent pharmacies, national accounts, and superstores.
In addition, Alliance's syndicated pharmacy salesforce, Skills in Healthcare, has been contracted to promote and sell the Goodbody Botanicals range to the 1,500 top performing independent pharmacy customers.
Sativa Chief Executive Henry Lees-Buckley said: "The Alliance distribution agreement is a significant step in Sativa's Goodbody Botanicals CBD Wellness brand's objective to grow market share with high street pharmacies, grocers, and superstores."
Media enquiries.
|
Abchurch Communications Julian Bosdet +44 (0)207 4594 4070 +44 (0) 7771 663 886 |
www.abchurch-group.com
|
For further information please contact:
|
Henry Lees-Buckley Chief Executive Officer Sativa Group Plc +44 (0) 20 7971 1255
|
Joseph Colliver Chief Financial Officer Sativa Group Plc +44 (0) 20 7971 1255
|
|
NEX Exchange Corporate Adviser
Corporate Finance Stephen Keys / Max Gould Cenkos Securities plc +44 (0) 20 7397 8900 |
Equity Sales Julian Morse Cenkos Securities +44 (0) 20 7397 8900 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
NEXUARBRRWUAORR
;